Lipid lowering for primary prevention

Lancet. 2009 Apr 4;373(9670):1152-5. doi: 10.1016/S0140-6736(09)60357-3.
No abstract available

Publication types

  • Review

MeSH terms

  • Aged
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / prevention & control*
  • Cause of Death
  • Cholesterol, LDL / blood
  • Female
  • Fluorobenzenes / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hyperlipidemias / blood
  • Hyperlipidemias / complications
  • Hyperlipidemias / prevention & control*
  • Male
  • Meta-Analysis as Topic
  • Primary Prevention / methods*
  • Proportional Hazards Models
  • Pyrimidines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Research Design*
  • Rosuvastatin Calcium
  • Secondary Prevention
  • Sulfonamides / therapeutic use*
  • Treatment Outcome

Substances

  • Cholesterol, LDL
  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrimidines
  • Sulfonamides
  • Rosuvastatin Calcium